Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.61
+7.4%
$2.00
$1.48
$13.44
$59.07M0.92561,618 shs620,874 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.91
+2.8%
$34.43
$26.32
$170.47
$10.79B1.866.92 million shs8.97 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.61
+0.3%
$26.00
$24.33
$31.54
$139.57B0.6139.16 million shs25.81 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-7.98%-17.13%-24.24%-18.03%-88.57%
Moderna, Inc. stock logo
MRNA
Moderna
-4.20%-19.76%-12.27%-34.68%-74.28%
Pfizer Inc. stock logo
PFE
Pfizer
-3.27%-4.05%-7.21%-7.56%-11.46%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.9701 of 5 stars
3.32.00.04.33.30.01.3
Moderna, Inc. stock logo
MRNA
Moderna
4.409 of 5 stars
4.01.00.04.62.42.51.3
Pfizer Inc. stock logo
PFE
Pfizer
4.9851 of 5 stars
3.33.04.24.23.33.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$12.20657.34% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.00111.39% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9229.72% Upside

Current Analyst Ratings Breakdown

Latest PFE, INO, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$217.76K271.25N/AN/A$5.16 per share0.31
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.37N/AN/A$28.33 per share0.99
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.19$3.86 per share6.38$15.81 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.99N/AN/AN/AN/A-118.17%-83.47%5/12/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.458.120.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest PFE, INO, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.67N/AN/AN/A$14.43 billionN/A
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.99%+2.50%121.99%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Shares Up 0.6% - Time to Buy?
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Sets New 1-Year Low - What's Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.61 +0.11 (+7.39%)
As of 03:15 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.91 +0.75 (+2.76%)
As of 03:10 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$24.61 +0.07 (+0.29%)
As of 03:16 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.